|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review显示文摘AIM To critically assess the available literature regarding the efficacy of thioguanine treatment in inflammatory bowel disease(IBD) patients, irrespective of the(hepato-) toxicity profile.METHODS A systematic literature search of the MEDLINE database using Pub Med was performed using the keywords 'thioguanine', '6-TG', 'thioguanine', 'inflammatory bowel disease', 'IBD', 'Crohn's disease', 'Ulcerative colitis' and 'effectiveness' in order to identify relevant articles published in English starting from 2000. Reference lists of the included articles were crosschecked for missing articles. Reviewed manuscripts concerning the effectiveness of thioguanine treatment in IBD were reviewed by the authors and the data were extracted. Data were subsequently analyzed with descriptive statistics. Due to the lack of standardized outcomes, a formal meta-analysis was not performed.RESULTS A total of 11 applicable studies were found that involved the effectiveness of thioguanine therapy in IBD. Eight studies were conducted in a prospectivemanner, in the remaining three studies, data was collected retrospectively. In total, 353 IBD-patients(225 patients with Crohn's disease, 119 with ulcerative colitis and nine with unclassified IBD) with prior azathioprine/mercaptopurine resistance and/or intolerance(n = 321) or de novo thioguanine administration(n = 32) were included for analysis, of which 228(65%) had clinical improvement on thioguanine therapy, based on standard IBD questionnaires, biochemical parameters or global physician assessments. Short-term results were based on 268 treatment years(median follow-up 9 mo, range 3-22 mo) with a median daily dose of 20 mg(range 10-80 mg). Discontinuation, mostly due to adverse events, was reported in 72 patients(20%). CONCLUSION The efficacy of thioguanine therapy in IBD patients intolerant to conventional thiopurine therapy is observed in 65%, with short term adverse events in 20% of patients. | Berrie Meijer Chris JJ Mulder Godefridus J Peters Adriaan A van Bodegraven Nanne KH de Boer | 2016 | World Journal of Gastroenterology2016，22，40： | 5 |
| 2 | On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprineor 6-mercaptopurine intolerant IBD patients显示文摘AIM: To determine the tolerability and safety profile of a low-dose maintenance therapy with 6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel disease (IBD) patients over a treatment period of at least 1 year.METHODS: Database analysis.RESULTS: Twenty out of ninety-five (21%) patients discontinued 6-TG (mean dose 24.6 mg; mean 6-TGN level 540 pmol/8×108 RBC) within 1 year. Reasons for discontinuation were GI complaints (31%), malaise (15%)and hepatotoxicity (15%). Hematological events occurred in three patients, one discontinued treatment. In the 6-TG-tolerant group, 9% (7/75) could be classified as hepatotoxicity. An abdominal ultrasound was performed in 54% of patients, one patient had splenomegaly.CONCLUSION: The majority of AZA or 6-MP-intolerant IBD patients (79%) is able to tolerate maintenance treatment with 6-TG (dosages between 0.3 and 0.4 mg/kg per d). 6-TG may still be considered as an escape maintenance immunosuppressant in this difficult to treat group of patients, taking into account potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity is worrisome and 6-TG should therefore be administered only in prospective trials. | Nanne KH de Boer Luc JJ Derijks Lennard PL Gilissen Daniel W Hommes Leopold GJB Engels Sybrand Y de Boer Gijsbertus den Hartog Piet M Hooymans Anja BU M(?)kelburg Barend D Westerveld Anton HJ Naber Chris JJ Mulder Dirk J de Jong | 2005 | World Journal of Gastroenterology2005，11，35： | 4 |
| 3 | Limitation of myocardial infarct size after primary angioplasty:Is a higher patency the only mechanism?显示文摘 | OTTERVANGER J P LIEM A De BOER M J | 1999 | Am Heart J1999，137，3： | 2 |
| 4 | 幽门螺杆菌感染的治疗显示文摘 | Wink A de Boer Guido N J Tytgat 游晓萍 姚炜 | 2001 | 英国医学杂志中文版2001，4，3： | 2 |
| 5 | Warming asymmey in climate change simulations显示文摘 | FLATO G M BOER G J | 2001 | Geophysical Research Letters2001，28，： | 1 |
| 6 | Differentiation and molecular detection of Canadian necrotic strains of Potato virus Y显示文摘 | Xu H Nie J De Boer S H | 2005 | Can J Plant Pathol2005，27，： | 1 |
| 7 | Interacting multiple model particle filter显示文摘 | BOERS Y DRIESSEN J N | 2003 | Radar Sonar and Navigation IEE Proceedings2003，150，5： | 1 |
| 8 | The diurnal inequality of the tide as a parameter for recognizing tidal influences显示文摘 | Boer P L Oost A P Visser M J | 1989 | Journal of Sedimentary Petrology1989，59，： | 1 |
| 9 | The Canadian Climate Centre spectral atmospheric general circulation model显示文摘 | Boer G J McFarlane N A Laprise R | 1984 | Atmosphere-Ocean1984，22，： | 1 |
| 10 | Do flame retar-dants threaten ocean life显示文摘 | De Boer J Wester P G Klammer H J C | 1998 | Nature1998，394，6688： | 1 |
| 11 | Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation显示文摘 | Onno J de Boer Floris Hirsch Allard C van der Wal Chris M van der Loos Pranab K Das Anton E Becker | 1997 | Atherosclerosis1997，，2： | 1 |
| 12 | The coupled model intercomparison project(CMIP)显示文摘 | MEEHL G A BOER G J COVEY C | 2000 | Bull Amer Meteor Soc2000，81，： | 1 |
| 13 | Coagulation disorders in septic shock 显示文摘 | Thijs L G de Boer J P de Groot M C | 1993 | Intensive Care Med1993，19，1： | 1 |
| 14 | Fatty acid export from the chloroplast molecular characterization of a major plastidial acyl-coenzyme a synthetase from Arabidopsis 显示文摘 | SCHNUR J A SHOCKEY J M BOER G I | 2002 | Plant Physiol2002，129，4： | 1 |
| 15 | Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy 显示文摘 | de Boer M J Ottervanger J P vant Hof A W | 2002 | J Am Coil Cardiol2002，39，11： | 1 |
| 16 | Protective efficacy Of Marek's disease virus(MDV)CVI-988 CEF65 clone against challenge infection with three very virulent MDV strains显示文摘 | de Boer G F Groenendal J E Boerrigter H M | 1986 | Avian Dis1986，30，2： | 1 |
| 17 | Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide显示文摘 | Siderov J Prasad P De Boer R | 2002 | Br J Cancer2002，86，1： | 1 |
| 18 | The Canadian Climate Centre second-generation general circulation model and its equilibrium climate显示文摘 | McFarlane N A Boer G J Blanchet J-P | 1992 | J Climate1992，5，： | 1 |
| 19 | Monocyte chemoattractant protein 1 ,interleukin 8, and chronic airways inflammation in COPD 显示文摘 | De Boer WI Sont JK Van Schadewijk A Stolk J van Krieken JH Hiemstra PS | 2000 | Journal of Pathol2000，190，5： | 1 |
| 20 | Comparison of ^99mTc-Sestamibi-^18 F-fluorodeoyglucose dual isotope simultaneous acquisition and rest-stress ^99m Tc-Sestamibi single photon emission computed tomography for the assessment of myocardial viability显示文摘 | De Boer J Shart RH Blanksma PK | 2003 | Nucl Med Commun2003，24，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员